These 20 women are 2018's Fiercest in the life sciences industry.
Read 2018's Fiercest Women in Life Sciences report!
The Chinese API maker at the heart of a global scare and recall of blood pressure medicines has been savaged in an FDA warning letter.
With the help of BioNTech and CEPI's $8.4 million, Imperial College London will work on a self-amplifying RNA vaccine platform.
CDMO Lonza is joining a rush of companies looking to cash in on China's eases drug regulations by building a biologics facility there.
Tris Pharma, which was slapped this year with a warning letter, is recalling three lots of an infants' pain reliever it says could be harmful.
Mylan has expanded its valsartan recall to all lots; a Japanese company is buying a Boehringer Ingelheim API plant, plus more manufacturing news.
CDMO Catalent is adding packaging equipment to the biologics plant in Indiana it picked up last year in a $950 million deal.
Just months after announcing a $65 million expansion to boost capacity and jobs at its North Carolina facility, Novo says it needs more of both.
A Chinese maker of heparin and APIs for oncology and other drugs is investing nearly $150 million as it targets innovative drugs for China.
After twice being sidelined by manufacturing-related CRLs, Ocular Therapeutix got FDA approval on Monday for its first eye drug.
Based in Oxford and slated to open in 2022, the center will focus on creating rapid, cost-effective ways of developing and manufacturing vaccines.
